Clinical Acceptability Of Trimetazidine Modified-Release 80 mg Once Daily Versus Trimetazidine Modified-Release 35 mg Twice Daily In Stable Angina Pectoris

INTRODUCTION: Trimetazidine (TMZ) is an anti-ischemic metabolic agent that has been shown to be efficacious in angina treatment, both in monotherapy and in combination. A new formulation of TMZ modified-release (MR) 80 mg was developed, which is to be taken once daily (od), instead of twice daily (b...

Descripción completa

Detalles Bibliográficos
Autor principal: Pozdnyakov, Yuri M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986675/
https://www.ncbi.nlm.nih.gov/pubmed/29779201
http://dx.doi.org/10.1007/s40119-018-0110-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986675/
https://www.ncbi.nlm.nih.gov/pubmed/29779201
http://dx.doi.org/10.1007/s40119-018-0110-5

Ejemplares similares